Waldenstrom macroglobulinemia - Development of diagnostic criteria and identification of prognostic factors

被引:94
|
作者
Owen, RG
Barrans, SL
Richards, SJ
O'Connor, SJM
Child, JA
Parapia, LA
Morgan, GJ
Jack, AS
机构
[1] Gen Infirm, HMDS Lab, Dept Hematol, Leeds LS1 3EX, W Yorkshire, England
[2] Bradford Royal Infirm, Dept Hematol, Bradford BD9 6RJ, W Yorkshire, England
关键词
Waldenstrom macroglobulinemia; immunophenotype; prognostic factors;
D O I
10.1309/4LCN-JMPG-5U71-UWQB
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
To establish whether a combination of morphologic and immunophenotypic criteria could be developed to more precisely define Waldenstrom macroglobulinemia (WM) and prognostic factors, we retrospectively assessed the clinical and laboratory, features of 111 cases of WM. Bone marrow infiltration by small lymphocytes was documented in each case; and diffuse, interstitial, nodular and paratrabecular patterns of infiltration were documented in 58%, 32%, 6%, and 4% of cases, respectively. Ninety percent were characterized by a surface immunoglobulin-positive, CDl9+CD20+CD5-CDI0-CD23- immunophenotype. The median overall survival from diagnosis was 60 months; univariate analysis revealed the following adverse prognostic factors: older than 60 years, performance status more than 1. platelet count less than 100 x 10(3)/muL (< 100 x 10(9)/L), pancytopenia, and diffuse bone marrow infiltration. Associated median survival it-as 40, 38, 46, 28, and 59 months, respectively. Multivariate analysis revealed age, performance status, and platelet count as prognostically significant, but stratification of patients according to the International Prognostic Index had limited value. We suggest defining WM by the following criteria: IgM monoclonal gammopathy; bone marrow infiltration by small lymphocytes, plasmacytoid cells, and plasma cells in a diffuse, interstitial, or nodular pattern; and a surface immunoglobulin-positive, CD19+CD20+CD5-CD10-CD23- immunophenotype.
引用
收藏
页码:420 / 428
页数:9
相关论文
共 50 条
  • [1] Prognostic factors add criteria to treat Waldenstrom's macroglobulinemia.
    Morel, P
    Duhamel, A
    Dimopoulos, M
    San Miguel, J
    Barlogie, B
    Kyle, R
    Leblond, V
    Dhodapkar, M
    Mc Coy, J
    Treon, S
    Gobbi, PG
    Merlini, G
    ANNALS OF ONCOLOGY, 2005, 16 : 261 - 262
  • [2] Developing diagnostic criteria in Waldenstrom's macroglobulinemia
    Owen, RG
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 196 - 200
  • [3] DIAGNOSTIC AND PROGNOSTIC DISCRIMINATION OF WALDENSTROM'S MACROGLOBULINEMIA
    Treon, S. P.
    HAEMATOLOGICA, 2018, 103 : 5 - 6
  • [4] Prognostic factors in symptomatic Waldenstrom's macroglobulinemia
    Merlini, G
    Baldini, L
    Broglia, C
    Comelli, M
    Goldaniga, M
    Palladini, G
    Deliliers, GL
    Gobbi, PG
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 211 - 215
  • [5] Prognostic factors and indications for treatment of Waldenstrom's Macroglobulinemia
    Kyle, Robert A.
    Ansell, Stephen M.
    Kapoor, Prashant
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2016, 29 (02) : 179 - 186
  • [6] PROGNOSTIC FACTORS IN WALDENSTROM MACROGLOBULINEMIA - A REPORT OF 167 CASES
    FACON, T
    BROUILLARD, M
    DUHAMEL, A
    MOREL, P
    SIMON, M
    JOUET, JP
    BAUTERS, F
    FENAUX, P
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1553 - 1558
  • [7] Waldenstrom's macroglobulinemia: prognostic factors and recent therapeutic advances
    Leblond, V
    Tournilhac, O
    Morel, P
    CLINICAL AND EXPERIMENTAL MEDICINE, 2004, 3 (04) : 187 - 198
  • [8] WALDENSTRoM MACROGLOBULINEMIA - A DIAGNOSTIC ENIGMA!
    Goel, Rohit R.
    Keimig, William C.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S613 - S613
  • [9] Development and validation of a prognostic model for Waldenstrom's macroglobulinemia (MW).
    Kyrtsonis, MC
    Dimopoulos, MA
    Vassilakopoulos, TP
    Angelopoulou, MK
    Repoussis, P
    Zervas, K
    Panagiotidis, P
    Siakantaris, MP
    Dimopoulou, MN
    Symeonidis, A
    Bourantas, K
    Vrakidou, E
    Xylouri, E
    Pangalis, GA
    BLOOD, 2003, 102 (11) : 273B - 273B
  • [10] Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression
    Dimopoulos, MA
    Alexanian, R
    Gika, D
    Anagnostopoulos, A
    Zervas, C
    Zomas, A
    Kyrtsonis, MC
    Anagnostopoulos, N
    Pangalis, GA
    Weber, DM
    LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2057 - 2061